Press releaseGlobe Newswire
Annexon
ANNX · NASDAQ
$3.83−$0.18 (−4.49%)TodayMarket closed ·
Prev close $4.01
Latest news
- Press releaseGlobe Newswire
Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones
- Press releaseGlobe Newswire
Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label Extension Study
- Press releaseGlobe Newswire
Annexon Appoints Renowned Retinal Surgeon and Biotechnology Entrepreneur Mark S. Blumenkranz, M.D., M.M.S. to its Board of Directors
- Press releaseGlobe Newswire
Annexon Reports First U.S. and European Patient Cohort of GBS FORWARD Study Demonstrated Rapid, Positive Clinical Responses in All Tanruprubart Treated Patients Within One Week
- Press releaseGlobe Newswire
Annexon Secures Strategic Credit Facility for up to $200 Million from Oxford Finance
- Press releaseGlobe Newswire
Annexon to Present Phase 2 ARCHER Baseline Characteristics Associated with Confirmed Best Corrected Visual Acuity 15-Letter Loss in Patients with Geographic Atrophy at ASRS 2026
- Press releaseGlobe Newswire
Annexon Reports First Quarter 2026 Financial Results, Portfolio Progress and Key Anticipated Milestones
- NewsAvi Kapoor
Apellis Pharmaceuticals, Centessa Pharmaceuticals, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
- Press releaseGlobe Newswire
Annexon Reports Fourth Quarter and Year-End 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
- Press releaseGlobe Newswire
Annexon to Host In-Person and Virtual KOL Event to Discuss Vonaprument for the Treatment of Geographic Atrophy
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- News
12 Health Care Stocks Moving In Friday's After-Market Session
- NewsAvi Kapoor
Stanley Black & Decker To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Tuesday
- NewsVandana Singh
Annexon's Investigational Drug Shows Rapid Recovery And Durable Benefit In Rare Neurological Disorder
- Press releaseBusiness Wire
Aviceda Therapeutics Appoints Ophthalmology Innovator and Industry Leader Dr. Emmett T. Cunningham, Jr. to Board of Directors
- Press releaseGlobe Newswire
Annexon Reports Fourth Quarter and Year-End 2024 Financial Results, Portfolio Progress and Key Anticipated Milestones
- Press releaseGlobe Newswire
Annexon Provides 2025 Outlook with Strong Momentum Accelerating into Breakthrough Year
- Press releaseGlobe Newswire
Annexon Reports Third Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones
- Press releaseGlobe Newswire
Annexon Reports Second Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones
- NewsAvi Kapoor
Bank of New York Mellon Posts Upbeat Earnings, Joins Archer Aviation, Rivian Automotive And Other Big Stocks Moving Higher On Friday
- News
10 Health Care Stocks Whale Activity In Today's Session
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.